SCHEMBL5059057

SCHEMBL5059057

CCOC(=O)c1ccc(C(=O)NCC(C)O)cc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
KDM4E B2RXH2 3/20 0.46
SMPD1 P17405 1/20 0.46
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
BAZ2B Q9UIF8 1/20 0.41
BAZ2A Q9UIF9 1/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
GAA P10253 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14339243 0.88 SMPD1 (0.48) HPGDSMPD1NPSR1ALDH1A1MAPT
SCHEMBL5063384 0.82 HPGD (0.44) HPGDKDM4EALDH1A1CYP4F2CYP4A11
SCHEMBL5059068 0.80 TAS1R3 (0.50) HPGDKDM4ENPSR1ALDH1A1CYP4F2
SCHEMBL1760466 0.79 CA12 (0.57) ALDH1A1CYP4F2CYP4A11BAZ2BBAZ2A
SCHEMBL5063207 0.79 NPSR1 (0.44) HPGDKDM4ENPSR1ALDH1A1MAPT
SCHEMBL5063269 0.77 LMNA (0.52) KDM4EALDH1A1MAPTCYP4F2CYP4A11
SCHEMBL878978 0.76 KDM4E (0.63) HPGDKDM4ESMPD1ALDH1A1MAPT
SCHEMBL9705735 0.72 HPGD (0.54) HPGDKDM4ESMPD1ALDH1A1KMT2A
SCHEMBL5858634 0.72 NR1H4 (0.55) HPGDSMPD1KMT2ARAB9AGAA
SCHEMBL4924813 0.72 TRPV1 (0.69) ALDH1A1MAPTMAPK1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161294-A1 Urea derivative, medicinal composition containing the same, and medicinal use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161294-A1 Urea derivative, medicinal composition containing the same, and medicinal use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161294-A1 Urea derivative, medicinal composition containing the same, and medicinal use of these KISSEI PHARMACEUTICAL CO., LTD. (JP) 2008-07-03 US disclosed
EP-1867639-A1 UREA DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE OF THESE Kissei Pharmaceutical Co., Ltd. (JP) 2007-12-19 EP disclosed
EP-1802615-A1 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2007-07-04 EP disclosed
WO-2006044955-A1 PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161294-A1 Urea derivative, medicinal composition containing the same, and medicinal use of these AVPR2, UTS2R, GPR119 HPGD 599/4885KDM4E 3239/4885SMPD1 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.